Form 4: Innoviva CFO Granted 27,609 Restricted Stock Units

Innoviva, Inc. Chief Financial Officer Stephen Basso was granted 27,609 restricted stock units, vesting over time with accelerated provisions.

Summary

• Stephen Basso, Chief Financial Officer of Innoviva, Inc. (INVA), was granted 27,609 shares of common stock in the form of time-vested Restricted Stock Units (RSUs).
• The transaction date for this acquisition was November 3, 2025, with an associated price of $18.11 per share.
• Following this transaction, Mr. Basso beneficially owns 50,890 shares.
• The RSUs will vest 25% on November 20, 2026, with the remaining balance vesting in twelve substantially equal installments every three months thereafter.
• Accelerated vesting provisions apply in the event of a 'change in control' where the RSU is not assumed or replaced, or upon an 'involuntary termination' within 24 months following a 'change in control,' subject to an effective release of claims.
• The grant was approved by the Compensation Committee of the Board of Directors.

Sentiment

Score: 7

Explanation: The RSU grant is a standard executive compensation event, generally positive for executive retention and alignment with shareholder interests, but neutral for immediate company performance. The future-dated transaction is unusual but doesn't inherently imply negative sentiment.

Positives

• The grant of 27,609 Restricted Stock Units (RSUs) to the Chief Financial Officer aligns his interests with long-term shareholder value.
• The time-vesting schedule encourages executive retention and sustained performance over several years.
• Accelerated vesting provisions in change-of-control scenarios provide a standard protection for executives, ensuring continuity or fair compensation during transitions.

Negatives

• Dilution of existing shareholder equity, albeit minor, due to the issuance of new shares upon RSU vesting.
• The future-dated transaction (November 3, 2025) and vesting (starting November 20, 2026) means the immediate impact on executive incentives is not current.

Risks

• No specific risks are mentioned in this Form 4 filing beyond the general risks associated with equity compensation, such as market price fluctuations affecting the value of the vested shares.

Future Outlook

The RSU grant establishes a future vesting schedule, with 25% of the shares vesting on November 20, 2026, and the remainder vesting in twelve equal quarterly installments thereafter, contingent on continuous service. This structure aims to incentivize long-term commitment and performance from the Chief Financial Officer.

Management Comments

• The Reporting Person was granted a time-vested restricted stock unit ('RSU').
• Twenty-five percent of the shares subject to the RSU vest on November 20, 2026 and the balance will vest in twelve (12) substantially equal installments thereafter on each three (3) month anniversary of the initial vesting date, in each case, provided the Reporting Person has provided continuous service to the Issuer through the applicable vesting date.
• The grant was approved by the Compensation Committee of the Board of Directors of the Company.

Industry Context

The grant of Restricted Stock Units (RSUs) to a Chief Financial Officer is a standard practice in the biotechnology and pharmaceutical industry, as well as across many public companies. This form of equity compensation is widely used to attract, retain, and motivate key executives by aligning their financial interests with the long-term performance of the company and its shareholders. The vesting schedule and change-of-control provisions are typical for such grants, reflecting common corporate governance and executive compensation strategies.

Comparison to Industry Standards

• The use of time-vested Restricted Stock Units (RSUs) for executive compensation is a common practice across the S&P 500 and comparable biotech firms, such as Amgen or Gilead Sciences, to promote long-term retention and align executive interests with shareholder value.
• A multi-year vesting schedule, with an initial cliff and subsequent quarterly vesting, is standard for executive equity grants, similar to those observed at companies like Vertex Pharmaceuticals or Regeneron Pharmaceuticals, ensuring sustained commitment.
• The inclusion of accelerated vesting clauses for change-in-control events or involuntary termination post-change-in-control is a prevalent feature in executive compensation agreements, mirroring practices at companies like Pfizer or Merck, designed to protect executives during corporate transitions.

Corporate Governance

Related Party Transactions

• The grant of Restricted Stock Units to Stephen Basso, the Chief Financial Officer, constitutes a related party transaction between the company and a key executive.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon vesting of RSUs, but also benefits from incentivized executive performance and retention.
• Employees: May signal stability in executive leadership and a commitment to long-term value creation.
• Management: Stephen Basso's compensation package is enhanced, aligning his financial interests with the company's long-term success and providing retention incentives.

Next Steps

• Continued service by Stephen Basso to Innoviva, Inc. to meet vesting conditions.
• Initial vesting of 25% of the RSUs on November 20, 2026.
• Subsequent quarterly vesting of the remaining RSUs over the following three years.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event – the grant of Restricted Stock Units to the Chief Financial Officer. While it aligns executive incentives with long-term shareholder value and supports retention, it does not provide new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Investors should maintain their current position and await more comprehensive financial disclosures.

Keywords

Innoviva, INVA, Stephen Basso, CFO, Restricted Stock Units, RSU, Equity Compensation, Executive Compensation, SEC Form 4, Insider Transaction, Stock Grant, Vesting